comparemela.com

Latest Breaking News On - Novel therapy - Page 8 : comparemela.com

Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Optimizing outcomesPatients withTranslating evidenceClinical practiceMetastatic renal cellRenal cell carcinomaKidney cancerMetastatic rccMetastatic kidney cancerAdvanced rccAdvanced kidney cancerIntermediate riskPoor riskIpi nivoNivo ipiTrio therapy

Scenario 1: A 47-Year-Old Man With Intermediate Risk Metastatic RCC

Expert perspectives on a patient scenario of intermediate risk metastatic renal cell carcinoma and corresponding management with combination immunotherapy.

Optimizing outcomesPatients withTranslating evidenceClinical practiceYear old man with intermediate risk metastaticRenal cell carcinomaKidney cancerMetastatic rccMetastatic kidney cancerAdvanced rccAdvanced kidney cancerIpi nivoNivo ipiTrio therapyImmune checkpoint inhibitorsLiver resection

Sequencing Later-Line Therapies for Metastatic Urothelial Carcinoma

A brief review of second-line and subsequent treatment strategies in metastatic urothelial carcinoma and novel therapies being explored in this space.

Urothelial carcinomasLater line therapiesMetastatic urothelial carcinomaBladder cancerUrothelial cancerUrothelial carcinomaLater line therapyLater line treatmentEnfortumab vedotinEv 301Ev 201Sacituzumab govitecanTrophyu 01Novel therapy

Novel Therapy in Urothelial Carcinoma: An Evolving Treatment Landscape

Closing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.

Urothelial carcinomasUrothelial carcinomaBladder cancerUrothelial cancerNovel therapyCombination therapyCheckpoint inhibitorsTargeted therapyEnfortumab vedotinNeoadjuvant therapyNeoadjuvant treatmentAdjuvant therapyAdjuvant treatmentCheckmate 274Ambassador trialCirculating tumor dna

Metastatic CRPC: Advent of PARP Inhibitors

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Key updatesMetastatic prostate cancer treatmentProstate cancerMetastatic castration resistant prostate cancerCastration resistant prostate cancerParp inhibitionParp inhibitorsNovel therapyCombination therapyDoublet therapyPropel trialPropel studyMagnitude trialMagnitude studyTalapro 2

vimarsana © 2020. All Rights Reserved.